Corporate History

Medizone International, Inc. Corporate History

Medizone International, Inc. (OTCBB: MZEI) was originally organized to develop treatments for a family of viruses known as lipid enveloped. Diseases such as Hepatitis B and C, HIV/AIDS, Herpes and Epstein Barr are included in this family of common viruses.

While the company still believes there remains great promise in treating many human afflictions with properly administered 03 mixtures, this is no longer our focus at this time.

As of 2008 we began pursuing a new initiative that has since shown great promise in the area of hospital disinfection.

By redirecting the company into this area of growing global concern, management and Medizone’s science team rightly believed that a revenue stream could be developed quickly and at far less cost than through the pursuit of human therapies.

A series of research initiatives spanning 2009 through to late 2010 (investigating new and innovative equipment and protocols for use in destroying the main causative agents of hospital acquired infections) resulted in an unprecedented success across a broad spectrum of bacteria, spores, fungi and viruses.

The primary causative agents of HAI – to which AsepticSure boasts a minimum EPA validated kill of >5 logs, while independent research routinely confirms >6 logs for all bacterial and viral pathogens:

  • C difficile
  • E-coli
  • Pseudomonas aeruginous
  • MRSA  – Methicillin-Resistant Staphylococcus Aureus
  • VRE

MRSA – Methicillin-Resistant Staphylococcus Aureus

This is a strain of Staphylococcus aureus bacteria (“staph”) that is resistant to the broad-spectrum antibiotics commonly used to treat it. MRSA is often fatal.Staphylococcus aureus bacteria

According to the AAOS Study, “the number of hospital admissions for MRSA has exploded in the past decade. By 2005, admissions were triple the number in 2000 and 10-fold higher than in 1995. In 2005, in the United States alone, 368,600 hospital admissions for MRSA — including 94,000 invasive infections — resulted in 18,650 deaths. The number of MRSA fatalities in 2005 surpassed the number of fatalities from hurricane Katrina and AIDS combined and is substantially higher than fatalities at the peak of the U. S. polio epidemic.”

Estimated cases of hospital-acquired infections Selected resistant bacteria U.S. 2002
Antibiotic-Resistant Bacteria Estimated Cases
Methicillin/S. aureus 102,000
Methicillin/CNS 130,000
Vancomycin/enterococci 26,000
Ceftazidime/P. aeruginosa 12,000
Ampicillin/E. coli 65,000
Imipenem/P. aeruginosa 16,000

Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control or “CDC” (CDC Report 17 Oct, 2007, copy on file with the Company), as one of the greatest threats to public health and safety in the industrial world.

See CDC Report here:


This concern was reflected in an article recently published in the Science Magazine The Bacteria Fight Back , Vol. 321, No. 5887. (18 July 2008), pp. 356-361, by Gary Taubes which estimated that hospital-based infections in 2006 accounted for almost 100,000 deaths in the US alone.

Corporate Redirection towards Full Hospital Decontamination since 2008

As stated above, early in 2008 the Company’s management and board of directors began to consider other applications of the Company’s core technologies and new technologies with lower development costs with the objective of moving the Company to revenue production in the shortest period of time.

Since that time, management has succeeded in positioning the Company and its recently developed flagship disinfection and decontamination technology, AsepticSure, in readiness for what it believes will be a phenomenal growth opportunity in the field of hospital sterilization. This change in focus was based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community.

Management determined in early 2008 that there was an outstanding opportunity to build on the Company’s experience with ozone technologies and its bio-oxidative qualities in pursuing this initiative. The Company subsequently shifted its (then) near term efforts towards one of its founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids (blood, serum, and plasma and its fractionates) as well as all biologically contaminated equipment and spaces.

The Company believes that Medizone’s unique ozone generating technologies can and will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as “the silent epidemic” (American Academy of Orthopedic Surgeons, May 2008, copy on file with the Company (“AAOS Study”), a reference to MRSA (methicillin-resistant staphylococcus aureus) infection.

Today Medizone is poised to tackle the problems associated with hospital acquired infections ‘head on’ with the already underway roll out of its first production units of AsepticSure.


MRSA Breaking Out

MRSA has gained tremendous ground since the 1970’s and 1980’s. In the mid-1980s, typically only 1% to 5% of all S. aureus isolates were methicillin-resistant, says Henry Chambers, an infectious-disease specialist at the University of California, San Francisco.  A bug developed that was both far more difficult to treat and, as Chambers says, “pretty adaptive to surviving in hospitals.” Today, 70% to 80% of all S. aureus strains found in hospitals are multidrug-resistant MRSA.





Medizone International, Inc. Prior to 2008

Prior to 2008 the Medizone focus was:

(i) seeking regulatory approval of a precise mixture of ozone and oxygen, and its process of inactivating lipid-enveloped viruses for the intended purpose of decontaminating blood and blood products and assisting in the treatment of certain diseases;

(ii) developing or acquiring the related technology and equipment for the medical application of its products, including a drug production and delivery system; and

(iii) applying its novel technology to the problem of nosocomial infections world-wide. Beginning in 2008, management has re-positioned the Company to pursue an initiative in the field of hospital sterilization.

Medizone International, Inc. (OTCQB: MZEI)

350 East Michigan Avenue – Suite 500
Kalamazoo, MI 49007

Telephone: (269) 202-5020

Email: [email protected]

Media and Investor Relations:

John Pentony

Medizone International, Inc.

Telephone: (269) 202-5020

Email: [email protected]

Social Media